GATC Health Files Suite of Patents for Multiomics-Based Predictive Disease Detection and Treatment

GATC Health Corp, a technology company revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, today announced it filed five patent applications with the US Patent and Trademark Office. These patent applications represent productizations of the company’s groundbreaking Multiomics Advanced Technology™ (MAT) to address individuals’ viral immune response, cardio-pulmonary risk, depression and anxiety treatment, medical cannabis treatment and medical psilocybin treatment.

“Each of these ‘engines,’ as well call them, represents a dual opportunity for our company. First, we provide personalized early diagnostic and treatment tools to healthcare providers, clinicians and patients through value-added channel partners. Second, we are continually collecting extremely valuable multiomics data. This proprietary data fuels our drug discovery and development efforts by improving our AI platform, as well as providing a significant revenue stream,” stated Jeff Moses, President of GATC Health.

Unlike other DNA-based diagnostic tools, GATC Health’s engines analyze billions of biological data points. Competitors typically rely on low-cost SNP chip methods, which usually analyze hundreds of thousands of data points. GATC Health’s diagnostic and treatment engines use a combination of whole genome or exome analysis and other pertinent omic information, such as metabalomic, proteomic, transcriptomic or epigenomic data, to provide actionable, personalized reports for patients and their clinicians. MAT has the documented ability to analyze 2,500 whole exome datasets at 100x read depth in approximately seven minutes.

“We understand there are other companies analyzing genetic data to help determine health risks and treatment options,” noted Ian Jenkins, the company’s Chief Scientific Officer. “We think they make two critical mistakes. First, many of these competing tests are based on false assumptions regarding the diseases or treatments they are targeting, limiting the accuracy and value of their results. Second, they use ‘low resolution’ data to hit certain price points. This forces them to further narrow their focus, potentially missing critical data that could be significant to the individual being tested.”

*   *   *

About GATC HealthGATC Health Corp is a pioneering technology company using whole genome analysis and multiomics-based artificial intelligence to revolutionize disease detection and drug discovery. The company’s patent pending AI platform reduces risk, time and costs for life science companies by digitally reproducing the human body to find non-obvious answers to biology’s most complex questions. GATC Health is accelerating healthcare’s transition to predictive, individualized medicine.Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities.  This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information.  The Company reserves the right to modify or amend the information contained herein.